Trigeminal Nerve Stimulation - An Integrated Neuromodulation Platform
NeuroSigma, Inc. is developing and commercializing trigeminal nerve stimulation (TNS) for a variety of neurologic and psychiatric disorders. TNS is unique among neuromodulation therapies because it can be delivered via a non-invasive external trigeminal nerve stimulation (eTNS™) system, or a minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system. NeuroSigma is investigating TNS as a treatment for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).
The Monarch™ eTNS system is NeuroSigma’s lead product and has received approval in the European Union and Canada as a treatment for epilepsy and depression. For more information on the Monarch, please visit our specialty site.
|
|
CAUTION: In the United States, both eTNS™ and sTNS™ are investigational devices and are limited by Federal (or United States) law to investigational use.
To learn more about the Monarch eTNS System and its treatment of TNS please visit our specialty site.